HOLX vs PPCB · P/E 32, rev $4.10B vs P/E 0.0, $3.9M cap
Hologic Inc (HOLX) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Hologic Inc (HOLX) is a medical instruments & supplies company listed on NASDAQ.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported HOLX revenue for 2025-09-27 was $4.10B. Net income was $565.7M. Revenue was up 1.7% from 2024-09-28 to 2025-09-27. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
PPCB does not have a complete income-statement cache yet.
HOLX currently screens at market cap $16.97B and trailing P/E 31.5. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the HOLX and PPCB stock pages for the full models.
Not investment advice.